How do you approach using CD 19/20 levels to redose Rituximab for ANCA associated vasculitis?

At what CD 19/20 level do you redose? Is this lab dependent? Do you also use these levels to instruct patients when to get vaccinated?

2 Answers

Mednet MemberInvited Expert

Rheumatology · Mayo Clinic College of Medicine

Answered on

In the MAINRITSAN 2 trial, a tailored rituximab regimen adapted to ANCA-positivity or ANCA-titre change and/or circulating CD19+ B cell repopulation was compared with fixed-schedule rituximab infusions.

There was no significant difference in relapse rates between the fixed-dose and tailored-dose arms...

Join for free or sign in to see the full answer

Mednet Member

Rheumatology · Wright State University

Answered on

CD 19+B cell latency may serve as a surrogate for individualized therapy with Rituxan.

Join for free or sign in to see the full answer